Welcome to Coloplast

World leader in Intimate Healthcare
Coloplast is world-class in dealing with medical problems that are deeply personal and private in nature. This holds true across all current business areas: Ostomy Care, Urology & Continence Care and Wound & Skin Care. The more intimate the problem, the greater the requirement to come closer to customers, understand their world and develop solutions which are sensitive to their special needs. This is where Coloplast excels.
People who have intimate health care needs

Ostomy Care
Ostomy users have typically suffered from colorectal cancer, bladder cancer or Inflammatory bowel disease

Urology & Continence Care
Continence users typically have spinal cord injuries and are often young people who have been involved in accidents.

Wound & Skin Care
Wound care users are typically treated for exuding and/or chronic wounds caused by disease or bed sore.
Products that make life easier for people with intimate healthcare needs

**Ostomy Care**
Ostomy products include ostomy bags for people who have had a stoma, i.e. a surgical procedure in which part of the intestine is brought out to the surface of the abdomen.

Ostomy bags consist of either a skin-adhesive plate with an attached bag or two separate parts in which the bag is replaced more often than the adhesive plate. A good ostomy bag is discreet and makes the user feel comfortable.

**Urology & Continence Care**
Continence products include intermittent catheters to help users empty their bladder quickly and easily. It also includes urine bags to help users collect leakage.

Urology products for include stents for surgical stone removal. Female products include sub-urethral tapes to restore continence and mesh for surgical prolapse repair. Male products include penis implants to alleviate erectile dysfunction and prostatic catheters.

**Wound & Skin Care**
Wound care products include dressings, which are attached to the wound using gauze or a built-in adhesive. The Biatain Ag-dressing series contains silver, which can kill bacteria, including those resistant to antibiotics. The Biatain Ibu-series contains ibuprofen, which reduces wound pain.

Skin care products include disinfectant liquids and lotions and are used primarily to protect skin exposed to body fluids, retaining skin moisture, and for bathing, cleansing and treating wounds.
50 years of innovation...

1. Generation
- Zinkoxide
  - 1957

2. Generation
- Karaya
  - 1972

3. Generation
- Curagard
  - 1978

4. Generation
- Swiss roll Assura
  - 1991

5. Generation
- Double layer SenSura
  - 2006
...and 50 years of growth

CAGR +24%


Ostomy care
Urology & Continence care
Wound & Skin care
Sales of intimate healthcare products of DKK 8bn

2006/07 sales

- Ostomy care: 39%
- Urology & Continence care: 40%
- Wound & Skin care: 16%
- Other: 6%

Region sales:
- Europe: 80%
- The Americas: 14%
- Rest of World: 6%
Ostomy Care Market

Coloplast revenue in 2006/07 DKK 3.1bn

Market size: DKK 10bn

Market growth: 3-5%

For people who have lost their normal bowel- or bladder function typically due to cancer (80%) or inflammatory bowel diseases

Main competitors are ConvaTec and Hollister Inc.

Ambition to become global market leader and to reach two-digit market share in the US within 2-4 years
Ostomy Care

<table>
<thead>
<tr>
<th></th>
<th>2006/07</th>
<th>2005/06</th>
<th>Organic Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Year</td>
<td>3.107</td>
<td>2.867</td>
<td>9%</td>
</tr>
<tr>
<td>Q4</td>
<td>804</td>
<td>753</td>
<td>8%</td>
</tr>
</tbody>
</table>

Primary driver: SenSura ostomy bag continues to gain market share and has been launched in 18 markets. With the continued global roll-out we expect this momentum to be maintained.

Easiflex and Assura 2 piece continued sale growth

US growth exceeded 20%

Solid product pipeline and new launches will ensure growth momentum is maintained.
Urology & Continence Care Market

Coloplast revenue in 2006/07 DKK 3.2bn

Market size: DKK 17bn

Market growth: 8-10%

Global market leader in continence consumables with 20-25% market share

Among global market leaders in urological specialties with 10% market share

Strong position in the US market established with the acquisition of urology business

European market leadership reinforced with 30% market share
Urology and Continence Care

<table>
<thead>
<tr>
<th></th>
<th>DKK million</th>
<th>2006/07</th>
<th>2005/06</th>
<th>Organic Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Year</td>
<td></td>
<td>3.199</td>
<td>2.233</td>
<td>11%</td>
</tr>
<tr>
<td>Q4</td>
<td></td>
<td>823</td>
<td>754</td>
<td>8%</td>
</tr>
</tbody>
</table>

Note: FY 05/06 includes acquired business from June

Continence:
Sales growth driven by intermittent catheters and urine bags.
Conveen Optima is now launched in 11 countries and continues growth momentum

Urology:
Acquired urology business shows growth in line with market growth.
Bolt-on acquisition in November 2007 of Levera, the next generation of sling therapy for male Stress Urinary Incontinence (SUI)
Wound & Skin Care Market

Market size DKK 13bn, growing at 5-7%
Coloplast revenue in 2006/07 DKK 1.3 bn. 13% markets share in EU and 2% in the US
Biatain - Ibu launched in 14 markets

Market size in DKK bn

<table>
<thead>
<tr>
<th>Category</th>
<th>Acute</th>
<th>Chronic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dry wound healing</td>
<td>11</td>
<td>8</td>
</tr>
<tr>
<td>Moist wound healing</td>
<td>8</td>
<td>11</td>
</tr>
<tr>
<td>Drugs and bio products</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>VAC</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>Total</td>
<td>28</td>
<td>26</td>
</tr>
</tbody>
</table>

Share of Moist Wound Healing market EU and US

- ConvaTec: 22%
- Smith & Nephew: 17%
- Coloplast: 12%
- Mölnlycke: 10%
- J&J: 8%
- 3M: 7%
- Urgo: 8%
- Other: 16%
## Wound and Skin Care

<table>
<thead>
<tr>
<th></th>
<th>2006/07</th>
<th>2005/06</th>
<th>Organic Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Year</td>
<td>1.269</td>
<td>1.223</td>
<td>6%</td>
</tr>
<tr>
<td>Q4</td>
<td>330</td>
<td>318</td>
<td>6%</td>
</tr>
</tbody>
</table>

**Sales growth driven by Biatain foam dressings**

The concept of Biatain-ibu is well received by customers, but sales performance is still below expectations.

New strategy under implementation, which is expected to deliver double-digit growth within 2 years.
Trends in the Intimate Healthcare Market

- Demographics: +
- Consumer healthcare awareness: +
- Emerging markets: +
- Surgical and medical trends: -/+ (Health Care reforms)
- Reimbursement reforms: -
- Group buying and tender bid process: -/+ (Health Care reforms)
- Focus on overall treatment costs: +
- Parallel import: -

The demand for products and services will continue to grow in terms of volume, but pressure on prices and margins will continue.

Market growth within Coloplast's business areas is approx. 6%
Model for continued price increase

1. New products to drive growth
   - Increase R&D from 3% to 6% of sales
   - Both external and internal R&D
   - Double speed of innovation and
   - Triple pipeline value

2. Organisation tuned to optimise time to market (March 2007)
   - FIGARO From Innovation to Global Roll-Out of new products
   - New processes for:
     - R&D
     - Marketing & Sales
     - Operations

3. Customer focus
   - Continue successful Key Player / NPD strategy at hospitals
   - RACE: Support NPD strategy with Retention and Conversion in the community

New products to deliver higher value in proven health economics model and attract higher price.
The fundamental change in stakeholder structure and decision power

Degree of influence

<table>
<thead>
<tr>
<th>Year</th>
<th>1980</th>
<th>1990</th>
<th>2000</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>End users</td>
<td>Low</td>
<td>Medium</td>
<td>High</td>
<td>Low</td>
</tr>
<tr>
<td>Doctors</td>
<td>Medium</td>
<td>Low</td>
<td>Medium</td>
<td>Low</td>
</tr>
<tr>
<td>Nurses</td>
<td>Low</td>
<td>Medium</td>
<td>High</td>
<td>Low</td>
</tr>
<tr>
<td>Retailers / prof. buyers</td>
<td>Low</td>
<td>Medium</td>
<td>High</td>
<td>Low</td>
</tr>
</tbody>
</table>
Mentor acquisition strengthened Coloplasts market position

**Strategic rationale**
- Targeting all key decision-makers within urology, i.e. hospitals, urology wards and primary care providers
- Enlarging the scope of continence care business into urology
- A solid position in the US urology market
- Strengthening our European market position
- A comprehensive portfolio of products and services

**Transaction facts**
- Price DKK 2.9 bn.
- Sales DKK 1.5bn
- EBITDA DKK 262m
- Closing date: 2 June 2006

**Status**
- Integration complete
- Annual synergies of DKK 75m
- Growth returned to market rate
The big picture of 2006/07

**Executing on strategy**
- Integration of Mentor complete and synergies and growth in place
- New organization in place
- Transfer of production to Hungary and China to plan
- Divestment of Breast Care and Brachy Therapy

**Organic sales growth up from 8% to 10%. Sales of DKK 8bn.**

**Non-recurring costs of DKK 552m from**
- integration costs of Mentor
- changing the organization
- Transferring production
- Goodwill write down

**Underlying EBIT 16%**
- on par with last year, and even including Mentor full year.

**Cash Flow of DKK 1bn.**
- Share buy-back and dividends
Organic sales growth up from 8% to 10%

Sales growth driven by launch of new products (Sensura and Conveen Optima) leading to higher prices and continued market share gains.

North America and Emerging markets continue solid double digit growth rates.

2006/07 sales

Growth by business

- Ostomy Care: 9%
- Urology & Continence Care: 11%
- Wound & Skin Care: 6%

Growth by region

- Europe: 9%
- North America: 16%
- Rest of World: 17%
Underlying EBIT-margin is 16% 2006/07

- Reported EBIT: 749
- Integration costs: 128
- Relocation US: 22
- Restructuring: 90
- Anniversary bonus: 29
- Goodwill HSC: 283
- Underlying EBIT: 1,301

16% margin

DKK 240 million
Solid cash generation
2006/07

EBIT 749
Intangible 179
Fixed assets 379
Goodwill 283
HSC 1.590
EBITDA 83
Working Capital 459
Capital 1.064
Interest & Tax 16
Other 1.099
CFFO 688
CAPEX 723
M&A
Free Cash Flow
Outlook for 2007/08

Sales growth

<table>
<thead>
<tr>
<th>Year</th>
<th>Sales Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001/02</td>
<td>14%</td>
</tr>
<tr>
<td>2002/03</td>
<td>11%</td>
</tr>
<tr>
<td>2003/04</td>
<td>10%</td>
</tr>
<tr>
<td>2004/05</td>
<td>8%</td>
</tr>
<tr>
<td>2005/06</td>
<td>8%</td>
</tr>
<tr>
<td>2006/07</td>
<td>10%</td>
</tr>
<tr>
<td>2007/08 Est.</td>
<td>10%</td>
</tr>
</tbody>
</table>

EBIT margin*

<table>
<thead>
<tr>
<th>Component</th>
<th>EBIT Margin 2006/07</th>
<th>EBIT Margin 2007/08</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reported</td>
<td>9.3%</td>
<td>0.8%</td>
</tr>
<tr>
<td>HSC</td>
<td>3.5%</td>
<td>0.3%</td>
</tr>
<tr>
<td>Non-recurring costs (DKK)</td>
<td>3.3%</td>
<td>0.2%</td>
</tr>
<tr>
<td>Underlying EBIT margin 2006/07</td>
<td>16.2%</td>
<td>16-17%</td>
</tr>
<tr>
<td>Mentor synergies 07/08 (DKK 75m)</td>
<td>0.8%</td>
<td>16-17%</td>
</tr>
<tr>
<td>Mentor integration costs 07/08 (DKK 30m)</td>
<td>0.3%</td>
<td>16-17%</td>
</tr>
<tr>
<td>GO relocation costs 07/08 (DKK 15m)</td>
<td>0.2%</td>
<td>16-17%</td>
</tr>
<tr>
<td>CAPEX 2006/07</td>
<td>839</td>
<td>700-800</td>
</tr>
<tr>
<td>New sites Hungary and China 2006/07</td>
<td>239</td>
<td></td>
</tr>
<tr>
<td>New site USA 2007/08</td>
<td>150</td>
<td></td>
</tr>
<tr>
<td>CAPEX 2007/08</td>
<td>700-800</td>
<td></td>
</tr>
</tbody>
</table>

Tax rate

<table>
<thead>
<tr>
<th>Component</th>
<th>Tax Rate 2006/07</th>
<th>Tax Rate 2007/08</th>
</tr>
</thead>
<tbody>
<tr>
<td>One-off gain 2006/07</td>
<td>26%</td>
<td>28%</td>
</tr>
<tr>
<td>Underlying tax rate 2007/08</td>
<td>12%</td>
<td>28%</td>
</tr>
</tbody>
</table>

Capital Expenditure

*EBIT margin 2007/08: GO relocation costs in 2007/08 of DKK 15m include a DKK 35m gain on sale of the Kokkedal site and DKK 50m costs from closing factories in Denmark.*
## Guidance for 2007/08

<table>
<thead>
<tr>
<th></th>
<th>2006/07 Guidance</th>
<th>2006/07 Actual</th>
<th>2007/08 Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organic sales growth</td>
<td>Approx 10%</td>
<td>10%</td>
<td>Approx 10%</td>
</tr>
<tr>
<td>EBIT margin</td>
<td>12-13%</td>
<td>9% (13%)</td>
<td>16-17%</td>
</tr>
<tr>
<td>CAPEX (DKKm)</td>
<td>600+200</td>
<td>839</td>
<td>Approx 700-800</td>
</tr>
<tr>
<td>Tax rate</td>
<td>Approx 26%</td>
<td>38% (26%)</td>
<td>Approx 28%</td>
</tr>
</tbody>
</table>
Long Term Financial Targets
Double digit sales growth

Continued sales growth in established markets through product innovation and expanding the market by influencing Key Opinion Leaders

Continued growth in emerging markets

Management focus on US to continue growth and market share gains
Changing the cost structure

EBIT
- Non-recurring costs: 9%
  - 4% Non-recurring costs
  - 3% Special items
- SG&A: 42%
- R&D: 4%
- Production: 39%
- Other Income: 1%

2006/07 Non-recurring costs Special items R&D SG&A Production Costs Pricing / Mix "Tomorrow"
Cost reductions from production transfer

- Cost base 2006/07 DKK 3.2bn
- Direct labor (index)
  - Denmark: 100
  - Hungary: 24
  - China: 6

Costs breakdown:
- Materials: 36%
- Wages: 26%
- Distribution: 14%
- Other: 24%
Split of sales value of production

2006/07
- USA / France: 20%
- China: 1%
- Hungary: 35%
- Denmark: 44%

2007/08 est.
- USA / France: 18%
- China: 4%
- Hungary: 40%
- Denmark: 38%

2011/12 est.
- USA / France: 21%
- China: 5%
- Hungary: 25%
- Denmark: 45%

100%
Long term financial targets

1. Economic Profit to double at least every five years
2. EBIT margin of 18-20%
Summary

Coloplast has well established brands and leading market positions in the attractive and growing intimate healthcare market.

Management is executing on a clear and focused strategy designed to capture growth and market share in existing and emerging markets through innovative new products that make life easier for people with intimate healthcare needs.

Coloplast is set to continue the strong track record of double digit sales growth, margin expansion and cash conversion to create shareholder value.
HSC: Goodwill write down of DKK 283 million and uncertain outlook for 2007/08

- DKK 283 million goodwill write off in HSC:
  - Increased competition among distributors
  - Significant loss of employees in Q4 impacts expected growth and earnings
  - Low profitability

- HSC uncertainty for 2007/08:
  - Significant loss of employees in Q1 may lead to lower sales and impact Coloplast's top-line growth for 2007/08.

- Coloplast GmbH
  - 65% of sales in Germany
  - Other manufacturers
    - 21%
    - 14%
  - HSC GmbH
    - 35% of sales in Germany
British healthcare reform

Two options for price adjustments:

1. To apply a uniform reduction of 12% to all the current reimbursement prices

2. To apply a pricing model based on product categorisation but cap price reductions at 35%

- Both options would reduce Department of Health’s annual spend of about £200m by £25m as opposed to the £27m previously announced
- The product classification has been revised after consultation with specialist nurse panels
# Income statement

<table>
<thead>
<tr>
<th></th>
<th>DKK million</th>
<th>Q4 2006/07</th>
<th>2005/06</th>
<th>Full Year 2006/07</th>
<th>2005/06</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net revenue</td>
<td>2.060</td>
<td>1.933</td>
<td>8.042</td>
<td>6.709</td>
<td></td>
</tr>
<tr>
<td>Gross profit</td>
<td>1.273</td>
<td>1.067</td>
<td>4.834</td>
<td>4.022</td>
<td></td>
</tr>
<tr>
<td>Gross margin</td>
<td>61.8%</td>
<td>55.2%</td>
<td>60.1%</td>
<td>59.9%</td>
<td></td>
</tr>
<tr>
<td>Operating profit before special items</td>
<td>275</td>
<td>132</td>
<td>1.061</td>
<td>939</td>
<td></td>
</tr>
<tr>
<td>Operating profit (EBIT)</td>
<td>-37</td>
<td>124</td>
<td>749</td>
<td>879</td>
<td></td>
</tr>
<tr>
<td>EBIT margin</td>
<td>-1.8%</td>
<td>6.4%</td>
<td>9.3%</td>
<td>13.1%</td>
<td></td>
</tr>
<tr>
<td>Net financial items</td>
<td>-57</td>
<td>-60</td>
<td>-154</td>
<td>-222</td>
<td></td>
</tr>
<tr>
<td>Pre-tax profit</td>
<td>-94</td>
<td>64</td>
<td>595</td>
<td>657</td>
<td></td>
</tr>
<tr>
<td>Net profit, continuing activities</td>
<td>-143</td>
<td>49</td>
<td>370</td>
<td>466</td>
<td></td>
</tr>
<tr>
<td>Net profit, discontinuing activities</td>
<td>-15</td>
<td>18</td>
<td>468</td>
<td>149</td>
<td></td>
</tr>
<tr>
<td>Minority interest</td>
<td>-1</td>
<td>-1</td>
<td>-1</td>
<td>-1</td>
<td></td>
</tr>
<tr>
<td>Coloplast share of net profit</td>
<td>-159</td>
<td>66</td>
<td>837</td>
<td>614</td>
<td></td>
</tr>
</tbody>
</table>

- EBIT 2006/07 is impacted by DKK 283 million goodwill write off
- Total non-recurring costs are DKK 552 million against DKK 230 million last year
- Underlying EBIT margin of 16%
On track for higher efficiency
- impact of DKK 240 million non-recurring costs

- Restructuring costs of DKK 90 million
- Relocation of manufacturing
- Organisational change

- Integration costs of DKK 128 million
- Integration of Mentor Business

- Relocation costs of DKK 22 million
- New joined US headquarter in Minneapolis

- Production costs impacted by DKK 35 million
- Administrative costs impacted by DKK 55 million

- Production costs impacted by DKK 35 million
- Distributions costs impacted by DKK 68 million
- Administration costs impacted by DKK 25 million

- Administrative costs impacted by DKK 22 million

Acquired urology and continence business
Underlying EBIT-margin in line with last year

2005/06

- Reported EBIT margin: 13.1%
- Non-recurring costs (DKK 230m): 3.4%
- Underlying EBIT margin: 16.5%

2006/07

- Underlying EBIT margin: 16.2%
- Non-recurring costs (DKK 552m): 6.9%
- Reported EBIT margin: 9.3%
## Cash flow

<table>
<thead>
<tr>
<th>DKK million</th>
<th>Full Year 2006/07</th>
<th>Full Year 2005/06</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBITDA</td>
<td>1.590</td>
<td>1.304</td>
</tr>
<tr>
<td>Change in working capital</td>
<td>-83</td>
<td>109</td>
</tr>
<tr>
<td>Interest and tax</td>
<td>-459</td>
<td>-550</td>
</tr>
<tr>
<td>Other</td>
<td>16</td>
<td>128</td>
</tr>
<tr>
<td><strong>Cash flow from operations</strong></td>
<td><strong>1.064</strong></td>
<td><strong>991</strong></td>
</tr>
<tr>
<td>CAPEX</td>
<td>-688</td>
<td>-387</td>
</tr>
<tr>
<td>M&amp;A</td>
<td>723</td>
<td>-2.631</td>
</tr>
<tr>
<td><strong>Cash flow from investments</strong></td>
<td><strong>35</strong></td>
<td><strong>-3.018</strong></td>
</tr>
<tr>
<td><strong>Free cash flow</strong></td>
<td><strong>1.099</strong></td>
<td><strong>-2.027</strong></td>
</tr>
<tr>
<td>Dividends</td>
<td>-184</td>
<td>-163</td>
</tr>
<tr>
<td>Share buy-back</td>
<td>-1.024</td>
<td>-103</td>
</tr>
<tr>
<td>Other cash changes</td>
<td>-3</td>
<td>91</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>-1.211</strong></td>
<td><strong>-175</strong></td>
</tr>
<tr>
<td><strong>Increase in net debt</strong></td>
<td>112</td>
<td>2.202</td>
</tr>
</tbody>
</table>
## Balance sheet

<table>
<thead>
<tr>
<th>DKK million</th>
<th>30/9 2006/07</th>
<th>30/9 2005/06</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance sheet total</td>
<td>7.750</td>
<td>7.982</td>
</tr>
<tr>
<td>Equity</td>
<td>2.398</td>
<td>2.804</td>
</tr>
<tr>
<td>Equity ratio (%)</td>
<td>31%</td>
<td>35%</td>
</tr>
<tr>
<td>Net interest bearing debt</td>
<td>3.181</td>
<td>3.069</td>
</tr>
<tr>
<td>Net debt to equity (%)</td>
<td>133%</td>
<td>109%</td>
</tr>
<tr>
<td>Net debt to EBITDA</td>
<td>2,00</td>
<td>2,20</td>
</tr>
<tr>
<td>Invested capital</td>
<td>6.874</td>
<td>7.996</td>
</tr>
<tr>
<td>ROAIC %</td>
<td>10%</td>
<td>15%</td>
</tr>
<tr>
<td>Economic profit</td>
<td>-227</td>
<td>349</td>
</tr>
</tbody>
</table>

- Share buy-back program of DKK 1.0bn completed. Target for Net debt to EBITDA is 2.0-3.5
- Economic profit is impacted by DKK 658 million goodwill write-off. Underlying growth in economic profit was 22%
Milestones

- 1957: Statutory meeting of Dansk Coloplast A/S
- 1978: The first subsidiaries
- 1982: Divisionalisation begins
- 1983: '3000 in 2000'
- 1989: Coloplast's share is admitted for listing on the Copenhagen Stock Exchange
- 2002: Factory in Hungary begins operations
- 2005: Announcement of 2012 objectives
- 2006: Acq. of Mentor’s Urology Division & Selling off Sterling + Moving of US HQ to Minneapolis
- 2007: Amoena & Brachytherapy divested

Coloplast's share is admitted for listing on the Copenhagen Stock Exchange

Several acquisitions: Amoena, Sween, SSL, HSC, Sterling

Announcement of 2012 objectives

Acq. of Mentor’s Urology Division & Selling off Sterling + Moving of US HQ to Minneapolis
Ownership structure

A-Shares carry 10 votes per share
B-Shares carry one vote per share

- Non-registered shareholders: 3,600
- Other Shareholders: 4,630
- Coloplast A/S: 3,980
- Foreign Institutional: 5,100
- Danish institutional: 9,500
- Holders of A-shares and their families: 17,676

B-Shares carry one vote per share

- Other Shareholders: 3,600
- Coloplast A/S: 44,400
- Foreign Institutional: 3,514
- Danish institutional: 4,630
- Non-registered shareholder: 3,980
- Holders of A-shares and their families: 5,100

Voting rights

- Holders of A-shares and their families: 44%
- Non-registered shareholders: 7%
- Other Shareholders: 11%
- Coloplast A/S: 10%
- Foreign Institutional: 8%
- Danish institutional: 20%
- Other Shareholders: 6%
- Foreign Institutional: 6%
- Danish institutional: 12%
- Non-registered shareholder: 67%